VistaGen Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering Treatment of Depression with AV-101
SAN FRANCISCO, CA--(Marketwired - March 07, 2018) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced …